Firm
Firms that made strategic PTAB hires say that insider expertise is becoming more valuable in the wake of USPTO changes
Aled Richards-Jones, a litigator and qualified barrister, is the fourth partner to join the firm’s growing patent litigation team this year
An IP lawyer tasked with helping to develop Brownstein’s newly unveiled New York office is eyeing a measured approach to talent hunting
Edward Russavage and Maria Crusey at Wolf Greenfield say that OpenAI MDL could broaden discovery and reshape how clients navigate AI copyright disputes
Sponsored
Sponsored
-
Sponsored by Patrinos & KilimirisMaria Kilimiris of Patrinos & Kilimiris explains how an interim ruling concerning the likelihood of confusion between Fenistil and Knistil highlights how pharmaceutical trademarks and product get-up are assessed under EU and national law -
Sponsored by RNA, Technology and IP AttorneysThere are strategic intellectual property considerations at every stage of a brand’s development. Ranjan Narula, Aditi Roy Chowdhury, and Simran Singh of RNA, Technology and IP Attorneys outline how startups can take a phased approach
-
Sponsored by Adams & AdamsMohamed Jameel Hamid and Alicia van der Walt of Adams & Adams unpack the African Continental Free Trade Area agreement, explain its impact on intellectual property, and outline practical strategies for brand owners across Africa
-
Sponsored by Cabinet M OproiuRaluca Vasilescu of Cabinet M Oproiu concludes a series on the use of artificial intelligence in patent practice by analysing how AI assistants affect the skilled reader’s perspective and the drafting of patent applications
-
Sponsored by Bird & BirdAnne-Raphaëlle Aubry of Bird & Bird explains how Section 1782 and Rule of Procedure 190 offer different pathways for cross-border evidence gathering in European patent disputes, highlighting timing, scope, and strategic considerations for litigants
-
Sponsored by Becerril, Coca & BecerrilMonica Sánchez of Becerril, Coca & Becerril explains how the Mexican intellectual property framework, including compulsory licences and the Bolar clause, works alongside emerging technologies to balance pharmaceutical innovation with public health access
